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ABSTRACT: Given the essential role played by protein kinases in regulating
cellular pathways, their dysregulation can result in the onset and/or
progression of various human diseases. Structural analysis of diverse protein
kinases suggests that these proteins exhibit a remarkable plasticity that allows
them to adopt distinct conformations in response to interactions with other
proteins, providing an opportunity for designing allosteric modulators. The
present work reports the results of an in silico screening study aimed at
identifying novel prospective allosteric binding sites in the paradigmatic p38α
MAP kinase. The process was carried out using a protein ensemble generated
from a 6 μs accelerated molecular dynamics simulation. The results of this
calculation were ﬁrst used to study the ﬂexibility of the protein using Principal
Component Analysis, followed by a Cluster Analysis aimed at producing an
ensemble of conformations representative of the sampling process.
Representative structures of the diverse clusters were subsequently screened for hot spots using FTMAP. The procedure
permitted the identiﬁcation of diverse allosteric sites of p38α already described in the literature including the DFG pocket, the
lipid binding pocket, the DEF site, the docking groove, the CD and ED sites, and the backside site as well as a novel site recently
reported: the A-loop regulatory site. Furthermore, the study also permitted the identiﬁcation of ten novel prospective allosteric
sites named NP1 to NP10, involving in most of the cases protein structural elements that control kinase activation including the
activation loop, the catalytic loop, the αC helix, the L16 loop, and the glycine-rich loop.
■ INTRODUCTION
Allosteric regulation is part of the intrinsic functioning of cells
as well as a deregulation mechanism of many cellular processes.
Allosterism is inherently connected to the plasticity of
proteins1,2 so that abnormalities aﬀecting protein ﬂexibility
due to either environmental changes or internal perturbations
such as mutations may impair their biological activity.3,4
Allosteric modulators are compounds that bind at a site
diﬀerent, often distant, from the active site to which the
endogenous ligand binds. This regulatory mechanism paves the
way for designing a new class of therapeutic agents.5
Protein phosphorylation is a paradigmatic example of
allosteric modulation. It involves the transfer of the γ-phosphate
group of ATP onto speciﬁc amino acids that exhibit a free
hydroxyl group in substrate proteins and peptides. The transfer
of the phosphate is associated with a conformational change in
the structure of the substrate, causing it to become activated or
deactivated.6 Protein phosphorylation is catalyzed by protein
kinases, one of the largest families of enzymes with more than
500 members encoded in the human genome.7 As fundamental
mediators of signaling pathways, dysregulation of protein
kinases can result in dramatic changes in the control of many
cellular processes resulting on the onset and/or progression of
various human diseases including inﬂammatory, cardiovascular,
metabolic, neurodegenerative diseases, and cancer.8
Due to their central role in cell signaling, protein kinases are
major targets for therapeutic intervention. At present there are
about 30 protein kinase inhibitors approved and more than a
hundred in clinical trials, in addition to those in a preclinical
state.9 The majority of approved inhibitors target the highly
conserved catalytic ATP binding pocket. However, due to the
high level of similarity of the site across family members, it is
very challenging to achieve highly selective and potent
compounds, required for the treatment of nonlife-threatening
diseases like many immunological dysfunctions. In order to get
more selective and potent inhibitors, interest has moved to
discover allosteric inhibitors aimed at exploiting structural
features and regulatory mechanisms that are unique to a
particular kinase.10−15
The discovery of allosteric modulators has been traditionally
associated with large high-throughput screening programs with
limited success. Alternatively, computational techniques have
demonstrated to be useful in identifying novel allosteric sites
through the study of protein plasticity.16 Protein ﬂexibility can
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be explained in terms of the rugged nature of the energy
landscape that exhibits multiple low energy minima connected
by low energetic barriers. Consequently, the inherent plasticity
of proteins is the result of a dynamic exchange between
diﬀerent conformational substates that take place on a range of
time scales from nanoseconds to seconds.17,18 Accordingly, the
structure of a protein should not be viewed as rigid but as an
ensemble of diverse conformations.19 More speciﬁcally,
allostery can be understood as a redistribution of the
conformational substates of the protein upon the perturbation
exercised by the eﬀector bound.20 Conformational sampling
methods allow access to conformations which are not the most
thermodynamically stable, but which are accessible at room
temperature and are signiﬁcant within the ensemble.21 Analysis
of the diverse substates of a protein permits identiﬁcation of
transient pockets that can be exploited to alter its enzymatic
activity via allosteric modulation.
The ultimate goal of the present study is the identiﬁcation of
prospective allosteric sites of the p38α MAP kinase. For this
purpose we carried out a detailed analysis of the ﬂexibility of
the enzyme using accelerated molecular dynamics (aMD)
calculations. These studies were subsequently used to identify
transient sites on the enzyme by means of an ensemble docking
approach using a set of diverse small molecules as probes. As
will be discussed later, the results of the present study suggest
that the procedure is robust enough to identify diverse allosteric
sites previously described in the literature and, furthermore, is
capable of identifying ten novel prospective allosteric sites.
■ METHODS
Molecular dynamics (MD) simulations were carried out on the
human p38α MAP kinase. However, due to the lack of
structures in the apo form with the A-loop completely solved,
we selected the crystallographic structure of mouse p38α (PDB
ID 1P38)22 due to its high resolution between residues 4 and
354 (2.1 Å). This structure corresponds to the unphosphory-
lated state and was solved without any ligand bound. In a
subsequent step, residues 48 and 263 were mutated in silico to
Leu and Thr, respectively, to get the sequence of the human
p38α by means of the MOE program.23 Finally, hydrogens
were added to all protein residues to their corresponding
protonation states at pH 7, using the Protonate3D function of
the MOE program.23 The mutation in silico of residues 48 and
263 does not produce any eﬀect on the structure of the protein.
To give support to this hypothesis we previously compared the
structures 1P38 and 1A9U (human unphosphorylated p38α
crystallized bound to SB203580). The overlay of the two
structures is good with an overall root-mean-square deviation
(rmsd) of 0.253 Å. Moreover, the backbones of the two
residues that are diﬀerent in mouse and human p38α sequence
exhibit their side chains in the same orientation. Actually, the
most important diﬀerences between the two crystal structures
are found in the A- and P-loops that are located far from the
position of the two residues.
The protein was soaked in a parallelepiped box of
equilibrated TIP3P water molecules. After removal of those
water molecules overlapping with the protein a total of 22,487
molecules remained. In addition, nine Na+ ions were added to
the solution to keep the neutrality of the system. Calculations
were carried out with the ﬀ99SB force ﬁeld24 at 300 K using the
NVT collective and periodic boundary conditions. A cutoﬀ of
10 Å was employed for the noncovalent interactions, and
electrostatic interactions were treated using the PME method.
Before starting the molecular dynamics calculation the structure
was energy minimized through 3000 steps using the steepest
descent method followed by 1000 steps of the conjugate
gradient method, in order to eliminate possible steric clashes.
During the ﬁrst 1000 minimization steps, harmonic positional
restrictions of 1 kcal/mol·Å−2 were applied to all the atoms in
the protein backbone. After minimization, the system was
heated to 300 K using a molecular dynamics calculation within
the NVT collective at a rate of 30K per 10 ps. Subsequently, the
system was equilibrated for 1 ns within the NPT collective,
followed by 1 ns within the NVT collective, keeping the
temperature at 300 K by means of the Langevin thermostat
with a collision frequency of 2 ps−1. The SHAKE algorithm was
used in all the MD simulations to constrain all bonds involving
hydrogen atoms to use an integration step of 2 fs.
Conformational sampling was performed by means of
accelerated molecular dynamics for 6 μs at 300 K, following
the protocol proposed by McCammon et al.25,26 and
implemented in the Amber14 program.27 Speciﬁcally, a biased
potential was applied to both the total and dihedral torsional
energies. The average potential energy (Ep) and the mean
dihedral energy (Ed) as well as the parameters αP and αD were
determined from a previous 50 ns classical molecular dynamics.
After accelerated molecular dynamics calculations were
completed, the eﬀects due to the bias were removed by a ten
order Maclaurin series reweighting of each conﬁguration to
recover the canonical ensemble.25 All the simulations were
carried out using the pmemd program of the Amber12
software27 on a graphics processing unit (GPU).
The results of the aMD calculation were subsequently used
to characterize protein ﬂexibility. For this purpose we ﬁrst
identiﬁed the invariant nucleus of the protein, deﬁned by the
set of residues that exhibit the smallest ﬂuctuations along the
MD trajectory. This was subsequently used to superimpose all
MD snapshots and compute a covariance matrix to carry out
Principal Component Analysis (PCA).28 This method ﬁlters
thermal ﬂuctuations and fast modes of local motions to reveal
the slower, correlated modes of motions that are more likely
associated with biological function. Furthermore, in order to
identify the diverse conformations the protein attains, we
carried out a hierarchical cluster analysis of the structures by
means of the average link algorithm,29 using the backbone Cα
root-mean-square deviation as a measure for the distance
between two conformations. Finally, mapping of the prospec-
tive allosteric binding sites was carried out using the FTMap
procedure.30 This method samples billions of positions of 16
diﬀerent small organic molecules used as probes on a grid
around the protein. Interaction energy is evaluated using ﬁrst
an empirical energy function, and then the best 2,000 poses are
energy minimized using the CHARMM potential including
solvation. A number of low energy poses are clustered, and the
clusters are ranked on the basis of the average energy. The
regions that bind several probe clusters are the predicted hot
spots.
The druggabiliy of each of the prospective allosteric binding
sites was assessed by means of the SiteMap program.31 The
program characterizes the druggability of a binding site through
the calculation of diverse properties that are evaluated by means
of SiteScore and Dscore functions. More speciﬁcally, SiteScore
measures the capacity of a pocket to bind ligands, whereas
Dscore assesses the druggability, the druglike character of a
pocket. Dscore allows the classiﬁcation of a binding site as
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druggable (high values), diﬃcult (intermediate values), and
undruggable (low values).
■ RESULTS AND DISCUSSION
Conformational Analysis of p38α. Analysis of the
ﬂexibility of p38α was carried out using 600,000 structures
extracted from the 6 μs accelerated molecular dynamics
calculation. Figure 1 shows the root-mean-square ﬂuctuations
(rmsf) of the diﬀerent residues of the protein. For the sake of
comparison is also shown the rmsf computed from the B-
factors of the crystallographic structure. As can be seen there is
good qualitative agreement between the two lines. Present
results on the rmsf of p38α agree with those reported
previously.32 Figure 2 shows pictorially the level of ﬂuctuations
of the Cα atoms of the diverse residues of p38α. As can be seen
residues of the invariant nucleus correspond to the central
residues of the αE, αF helices depicted in blue and green.
Analysis of Figures 1 and 2 suggests that the most ﬂexible
structural motifs of the protein include the glycine-rich loop,
the C-terminal segment of the activation loop, the N-terminal
end of the protein, the loop connecting helices αEF and αF,
and the β4-β5 loop, as well as the two structural elements
speciﬁcally found in MAPKs: the MAP kinase insertion (MKI)
motif and much of the C-terminal extension. Interestingly,
many of these structural elements play an important role in
p38α function. Speciﬁcally, the activation loop plays an
essential role in kinase activation, whereas the glycine-rich
loop is believed to prevent the solvent from entering the
catalytic site in addition to contributing to the positioning of
the ATP phosphate groups.33 Furthermore, the MKI motif and
the C-terminal extension are thought to be interfaces of the
interaction with other proteins,34 so that the observed ﬂexibility
must play an important role in the formation of these protein−
protein interfaces. The MKI motif forms part of the interface or
a coupling site known as DEF, whose accessibility would be
coupled with the activation of the kinase, since the
phosphorylation of this promotes site exposure.35,36 The
allosteric inhibitor of JNK1 Compound 2 exerts its function
binding to this site.10 Also, the MKI motif forms part of the
lipid recognition pocket, an allosteric regulatory site in p38α
with Compound 10 as the only inhibitor known,10 and is
believed to have a role in modulating the catalytic activity of the
protein kinase in vivo.37,38 Finally, the C-terminal extension is a
key element to keep MAPKs in an inactive conformation.
Other key domains involved in the regulation of p38α
activity exhibit intermediate ﬂexibility including the catalytic
loop, the N-terminal segment of the activation loop, the αC
helix, and the hinge region. The catalytic loop contains residue
Asp150 involved in the catalytic reaction of phosphorylation,
while residues Lys152 and Asn155 in the same loop, as well as
Asp168 in the DFG motif of the N-terminal segment of the
activation loop, participate in the positioning of the Mg-ATP.
The position of the αC helix is also key for the modulation of
the catalytic activity, since the conserved Glu71 forces the
position of Lys53 in the β3-strand, which is also key in
positioning the nucleotide at the active site. The hinge region
that articulates the movement between the N-terminal and the
C-terminal domains controls the establishment of this
important interaction between Glu71 and Lys53. A mechanism
that regulates the formation of this interaction and prevents the
intrinsic activity of p38α is the interaction between the L16
loop at the C-terminal extension and the αC helix.
Some structural features of the active conformation were not
sampled in the accelerated molecular dynamics simulation. For
instance, the active conformation of the activation loop found
in the crystalline structures of phosphorylated p38α was not
sampled, suggesting that attaining this conformation without
being phosphorylated must be considered as a rare event in the
dynamics of the protein.39 This result agrees with experimental
observation of the low level of basal activation of the
nonphosphorylated kinase. The DFG-out conformation,
found in the crystallographic structures of p38α bound to
type II inhibitors, is also not attained in the sampling process,
although the movement of the motif is partially captured in one
of the representative structures. This suggests that the binding
mechanism of the ligands that occupy the allosteric DFG
Figure 1. Root-mean-square ﬂuctuations of p38α Cα atoms of all
residues of p38α. In colors are those computed along the aMD
trajectory, whereas in gray are those computed from the B-factors of
the crystallographic structure according to the relationship rmsf = [3·
B/(8π2)]1/2. Speciﬁc structural elements are highlighted in diﬀerent
colors.
Figure 2. Flexibility of p38α. Residues with a rmsf of their Cα atoms
lower than 0.5 Å are shown in blue; residues with a rmsf between 0.5
and 3 Å are shown in green, and residues with rmsf larger than 3 Å are
shown in purple.
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allosteric site may proceed through an induced ﬁt mechanism as
supported by steered molecular dynamics simulations.40
Alternatively, it could also be possible that signiﬁcantly higher
simulation times are necessary. Indeed, in order to sample the
DFG-in to DFG-out transition previously reported MD
simulations of p38α were performed at 1000 K.41
Principal Component Analysis. The Cartesian coordi-
nates of the Cα corresponding to those residues with atomic
ﬂuctuations (rmsf) lower than 0.5 Å (see Figure 1) deﬁne the
invariant nucleus of the protein that was used to align the
600,000 structures collected during the sampling process. The
alignment of structures aims to eliminate the rotational and
translational movements in the subsequent analysis, focusing on
the structural diﬀerences between the diﬀerent states captured.
The superposition of the structures permitted the recomputa-
tion of atom ﬂuctuations to construct a covariance matrix that
was subsequently diagonalized to obtain its principal
components and eigenvalues. Visual inspection of the ﬁrst
ﬁve components, accounting for 63% of protein ﬂuctuations,
shows that only the ﬁrst two, PC1 and PC2, involve whole
protein motions (accounting for a 43% of protein ﬂuctuations),
whereas the three following involve motions at either the N- or
the C-terminus. Speciﬁcally, the PC1 component corresponds
to a bending motion involving the C-terminal and N-terminal
lobes (see Figure 3a). The motion encompasses the entire N-
terminal domain, while at the C-terminal domain involves the
MKI motif, the αG helix, the activation loop, and the α1L14/
αH loop. The PC2 component corresponds to a correlated
rocking motion involving the same structural elements
associated with the PC1 component, as can be seen in Figure
3b. Moreover, in the PC2 the MKI motif exhibits larger
ﬂexibility, while the N-terminal domain exhibits a smaller
ﬂuctuation, especially at the αC helix, the C-terminal extension,
and the β4/β5 loop. Similar ﬁndings in regard to the ﬂexibility
of p38α were reported by Bakan et al.42 The following principal
components involve one of the domains. Both components
PC1 and PC2 are connected with the expected movements
associated with p38α functionality, including binding to the
substrate and enzyme activation. PC3 and PC4 correspond to a
rocking motion of the N-terminus, and PC5 corresponds to a
rocking motion of the C-terminus similar to PC1, although the
activation loop exhibits less amplitude.
Figure 4 shows pictorially the projection of the 600,000
snapshots onto the subspace deﬁned by the two ﬁrst principal
components (PC1 and PC2) after reweighting. Inspection of
Figure 4 permits the identiﬁcation of two basins in the low
dimension representation of the free energy landscape. The
lowest energy minimum (minimum 1) is located at coordinates
(17.5, −20.5) and represents 235 structures, whereas minimum
2 is found at coordinates (−12.5, 10.5) and represents 164
structures. In order to understand the conformational features
of the structures representing these two minima, the
corresponding average structures were generated and energy
minimized. Comparison of the two structures shows a few
structural diﬀerences. Speciﬁcally, structures located in
minimum 2 are more open regarding the relative position of
some structural elements such as the αC helix, the C-terminal
extension, and the MKI motif than in minimum 1.
Furthermore, the activation loop in minimum 2 is closer to
the hinge region than in minimum 1. In order to understand if
the two minima represent active or inactive conformations and
DFG-in or DFG-out structures, we projected onto the PC1/
PC2 map a set of 43 crystallographic structures of p38α with
residues 7 to 345 solved, covering diﬀerential structural features
(see Figure 4). Interestingly, all the crystallographic structures
are located in the minimum 1 basin.
Figure 3. Representation of the two ﬁrst principal components. The
direction of the displacement of the Cα is shown by arrows, the length
of the arrow being proportional to the magnitude of the vibration of
the atom. For simplicity, the ﬁgure shows only arrows for vibrations
that result in displacements greater than 1 Å. The protein skeleton is
shown colored with a RWB (red to white to blue transition) gradient,
in order of lowest to highest contribution of the skeleton of each
amino acid to the major component. Calculations were carried out
with the NMWiz module installed in the VMD program:66,67 a)
representation of the PC1 and b) representation of the PC2.
Figure 4. Free energy map calculated from the projection of the
structures extracted from the aMD on the main components PC1 and
PC2. It shows the projection of the coordinates of p38α crystalline
structures deposited in the PDB and completely resolved between
amino acids 7 to 345 (PDB IDs: 1a9u, 1bl6, 1bl7, 1bmk, 1di9, 1m7q,
1ouk, 1ouy, 1ove, 1p38, 1r3c, 1w7h, 1w84, 1wbw, 1yqj, 1zzl, 2i0h, 2lgc,
2yix, 2zb0, 3ds6, 3dt1, 3gc7, 3gc8, 3gfe, 3itz, 3py3, 3rin, 3s3i, 3u8w,
4loo, 4lop, 1w82, 1w83, 1wbn, 1wbs, 1wbt, 1wbv, 3kq7, 3nnu, 3nnv,
3nnw). In addition, the 2OZA structure has been included, whose
phosphorylation loop was completed by homology modeling and
molecular dynamics calculations.49 These structures have been divided
into two groups with diﬀerent colors: in green, structures whose
activation loop is in a DFG-in conformation and in red, structures with
the activation loop in a DFG-out conformation. The structure of the
phosphorylated protein 3PY3 is represented by an orange circle.
Finally, the coordinates of the energy minima of the conformational
sampling and the representatives resulting from the analysis of clusters
are indicated.
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In order to get further insight into the features of the
structures representing the two minima, we also analyzed the
features of the regulatory spine (R-Spine) of the two structures.
The R-spine is a structural motif consisting of ﬁve amino acids
(notated as RS0-RS4), located at diﬀerent protein structural
elements whose relative position is considered to be essential
for the catalytic activity of protein kinases.43,44 Thus, in the
active conformation residue RS0 serves as an anchoring point
to residues RS1−RS4 that are linked consecutively. Speciﬁcally,
the side chain of RS0 interacts via a hydrogen bond with the
NH group of the skeleton of the RS1 residue in the HRD motif.
Moreover, residue RS1 interacts with residue RS2 of the
conserved DFG motif in the activation loop, which also
interacts at the active site with the Mg2+ ions that coordinate
ATP, participating in its correct arrangement. Residue RS2 also
interacts with residue RS3 of the αC helix, whose position is
vital for kinase activation, and residue RS3 interacts with the
residue RS4 in the β4 strand. Inactive conformations are those
structures that have the R-Spine distorted. They can be
classiﬁed into four groups (I−IV) depending on the position of
the amino acid of the R-Spine displaced in respect to the active
conformation.45 Thus, in the inactive conformation I the
activation loop adopts a DFG-out conformation, which results
in the disruption of the interactions of RS2 with residues RS1
and RS3, respectively. In the inactive conformation II the αC
helix moves to an αC-out conformation causing a disruption of
the interaction between residues RS3 and RS2 and between
residues RS3 and RS4, respectively. In the inactive
conformation III there is a misalignment of residue RS1 with
respect to the catalytically active conformation and the
subsequent loss of the interaction between residues RS0 and
RS1, resulting from the HRD-out conformation adopted by the
kinase. Finally, the inactive conformation IV, or rotated lobes,
occurs when the interaction between residues RS2 and RS3 is
lost, as the result of the relative rotation of the two domains.
In p38α the R-Spine is constituted by amino acids Asp205
(RS0), His148 (RS1), Phe169 (RS2), Leu75 (RS3), and Leu86
(RS4). Figure 5 shows the position of these residues in the
average structures of minima 1 and 2, as well as in the
crystalline structure 1P38. In the crystallographic structure the
distance between the amino acids RS2 and RS3 is larger than in
the active conformation due to the disposition of the activation
loop and to the rotation of the N- and C-terminal domains.
Accordingly, this structure can be considered as a type IV
inactive conformation. Analysis of Figure 5 suggests that the
average structure of minimum 1 exhibits the residues of R-
Spine in the same position to structure 1P38 and can
consequently be considered as an inactive conformation of
type IV. However, in the average structure of the minimum 2,
the hydrogen bond interaction between the residues RS0 and
RS1 is lost due to the conformation adopted by the catalytic
loop, suggesting that the structure can be classiﬁed as a type III
inactive conformation.
Identiﬁcation of Prospective Allosteric Binding Sites.
As mentioned above, allostery is inherently connected to
protein plasticity. Accordingly, in silico identiﬁcation of
allosteric binding sites requires the incorporation of protein
ﬂexibility in the screening process. This can be eﬀectively done
using an ensemble of conformations generated from a long MD
calculation.46 For this purpose, we selected a few structures
representing the 600,000 conﬁgurations extracted from the
aMD simulation. The selection was carried out by means of the
average linkage hierarchical clustering algorithm,29 using the
rmsd of the Cα atoms as a measure of distance between two
conﬁgurations. This procedure permitted grouping the
conﬁgurations into 15 clusters that were represented by the
structure with the closest rmsd to the average value,
respectively. Figure 4 shows the location of the representative
structures on the PC1/PC2 map. The representative structures
were subsequently used for screening prospective allosteric
binding sites.
The surfaces of the 15 representative structures were mapped
using the FTMap program.30 Figures 6a and 6b show the
aggregated results of the 15 calculations where the diverse
fragments are drawn for convenience on the crystalline
structure used as starting structure for the MD calculations
(PDB ID: 1P38). Shown in Figure 6a are those sites identiﬁed
that have been previously described in the literature, whereas
Figure 6b shows prospective allosteric binding sites not
previously described. Among the binding sites previously
described in the literature, the ATP pocket is the most
extensively sampled site including diverse fragments, being
identiﬁed in all 15 representative structures. Inspection of the
site shows that it includes, in addition to the ATP binding site,
other adjacent pockets used by Type I inhibitors, such as the
hydrophobic regions I and II.47 Moreover, despite the DFG-in/
DFG-out conformational transition not being observed during
the simulation, in one of the representative structures the N-
terminal segment of the activation loop appears slightly
displaced in the direction of the C-terminal domain so that
the FTMAP procedure is able to identify fragments that occupy
the DFG pocket. The allosteric binding sites associated with the
MKI motif, the lipid binding site, and the DEF site are also
identiﬁed.47 There are fragments that dock in sites that overlap
spatially with the structures of the allosteric ligands cocrystal-
lized with the p38α and JNK1 proteins.10 Fragments also bind
to the docking groove, which is a site of protein−protein
interaction that is presumed important in acquiring the active
Figure 5. Position of the residues that constitute the R-Spine in
minimum 1 (cyan), minimum 2 (purple), and in the crystal structure
1P38 (green).
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conformation and acts as a regulator of signal duration and
intensity,48−51 as well as its adjacent small ED and CD sites.
Several inhibitors directed to these sites have been reported for
ERK252,53 and JNK.54 The backside pocket that is suspected to
be the site of the inhibitor of p38α CMPD155,56 appears in
many of the structures. It is a wide pocket located behind the
hinge region between the end of the C-terminal extension and
the turn that connects strands β7 and β8. Finally, the procedure
also identiﬁes an allosteric site recently reported by this
laboratory, located between the ACE motif of the activation
loop, the αEF helix, the N-terminal end of the αG helix, and
part of the N-terminal segment of the activation.57
Additionally, ten prospective binding sites, not previously
described for the p38α protein or other MAP kinases named
NP1 to NP10, are shown in Figure 6b. The NP1 site is located
at the back of the beta sheets between the ends N-terminal and
C-terminal, which is in an area with a high ﬂexibility. This site
appears more or less extensively in seven of the 15
representative structures. Also in the area of the beta sheets
but next to the glycine-rich loop is the NP2 site, which is also
observed in seven of the 15 selected structures. The glycine-rich
loop or P-loop is an important structural motif in the
development of catalysis since it is thought that it protects
the solvent from the place where the catalytic reaction occurs
and also contributes to the positioning of the phosphate groups
of the ATP.33
The NP3 site is found in two of the representative structures
in which the αC helix adopts an inactive αC-out conformation.
This conformation is characterized by the loss of the ionic pair
between Lys53 (β3 strand) and Glu71 (αC helix), which is
essential for kinase activity, that is interrupted due to αC helix
displacement. This site coincides with the pocket found in
CDK2 using extrinsic ﬂuorophore 8-anilino-1-naphthalenesul-
fonate (ANS) as probe.11,12 In addition, there are crystallo-
graphic structures of a few protein kinases, including EGFR, B-
Raf, MEK1/2, PDK1, and Akt1, bound to inhibitors in
allosteric pockets arisen as a consequence of the αC helix
displacement that lie close to the NP3 site. Some of these
inhibitors belong to the type IIB class, like for example the
recently approved B-Raf inhibitors lapatinib and vemurafenib to
treat breast cancer and advanced melanoma, respectively.13
These compounds can be considered as dual inhibitors that
bind to the ATP and the NP3 sites. Other compounds that also
bind close to the NP3 belong to the type III class of inhibitors−
they do not use the ATP pocket like for example trametinib, a
recently approved inhibitor of MEK1 and MEK2.14 The NP4
site, also close to the αC helix, extends toward the L16 loop,
the catalytic loop, and the central segment of the activation
loop. All of these are essential structural elements in the control
of kinase activation or catalytic activity. The NP5 site is located
in ﬁve of the representative structures. It is interesting that in
one of these structures the activation loop is in a self-inhibited
conformation in that it is folded toward the ATP site, partially
occluding it as well as the catalytic loop. In this structure the
activation loop adopts a conformation that bears some
resemblance to that of the JNK3 structures with codes in the
PDB 4H36, 4H39, and 4H3B.58
The NP6 site appears in ten of the 15 representative
structures and is located behind the activation loop,
encompassing the surface between the catalytic loop, the
ACE motif of the activation loop, the αEF helix, the αEF/αF
loop, and the N-terminal end of the αF helix. The NP7 site
appears in four of the representative structures and is located
between the αD helix, the αF helix, the APE motif of the
activation loop, the catalytic loop, and the αF/αG loop. At the
other side of this loop and close to the C-terminal end of the
αF helix there is a prospective site, so-called NP9, that is found
Figure 6. Aggregated probe map of the aMD trajectory 15
representatives bound to the 1P38 crystallographic structure. a) Sites
already described in the literature: fragments binding to the ATP
pocket and adjacent hydrophobic pockets I and II are shown in purple
blue; fragments binding to the DFG pocket are shown in fuchsia;
fragments binding to the union of lipids pocket are shown in red;
fragments binding to the DEF site are shown in orange; fragments
binding to the docking groove are shown in light green; fragments
binding to the CD site are shown in magenta; fragments binding to the
ED site are shown in light blue; fragments binding to the backside
binding pocket are shown in yellow; and fragments binding to the A-
loop regulatory site are shown in dark blue. b) Prospective sites not
previously described in the literature.
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in two of the structures. Despite there being no inhibitor
described to bind to this site, there is a crystallographic
structure of p38α that shows a fragment of the TAB1 protein
bound to it that also occupies the docking groove.59 Binding of
the peptide has eﬀects on the conformation of the protein, so
that the N-terminal and C-terminal lobes close up to each other
as in the active conformation. Furthermore, the structure shows
the activation loop in a conformation diﬀerent to that found in
other nonphosphorylated proteins, which is compatible with a
cis autophosphorylation mechanism on the Thr180 residue. The
activation loop of MK2 also binds to this site as shown in the
crystallographic structure of the heterodimer p38α/MK260−62
and also is found as a prospective site by Bakan et al.63 and
Coleman et al.64 On the other hand, in another protein family
of MAPKs, JNK2, some of the amino acids of the αF/αG loop
and the latter of the αF helix are involved in the
autophosphorylation of this kinase.65 Near this site, between
the N-terminal end of the αE, the C-terminal helix αF, and the
N-terminal helix αH is located the NP8 site that appears in one
of the structures obtained and which is also involved in the
binding of the TAB1 protein fragment described above. Finally,
the NP10 site is found in 3 of the representative structures,
located at the C-terminal ends of the αG and N-terminal helix
of the α2L14 helix at the MAPK insertion and parallel to the
loop connecting them both and extends to the C-terminal
segment of the αH helix.
The results of the druggability assessment using the SiteMap
procedure are summarized in Table 1. A value of SiteScore of
0.80 is considered as an adequate threshold to discriminate
between sites suitable for ligand binding with submicromo-
lecular aﬃnity from sites not able to bind ligands with high
aﬃnity.31 On the other hand, values of Dscore allow the
classiﬁcation of a binding site as druggable (<0.98), diﬃcult
(0.98−0.83), and undruggable (>0.83). Inspection of Table 1
indicates that known binding sites such as the ATP pocket and
the lipid binding site are well ranked using both parameters. In
contrast, the docking groove, including the adjacent ED and the
CD sites, is not well qualiﬁed as a binding site capable of
binding druglike compounds with high aﬃnity. Similar results
are obtained for the recently reported A-loop regulatory site or
the backside site. In these cases, it may be necessary to consider
adjacent pockets in order to design new drugs targeting these
sites. Regarding the novel sites identiﬁed in the present study,
six of them have SiteScore values below the threshold: NP1,
NP3, NP4, NP5, NP6, and NP7. Moreover, NP4 and NP7 are
druggable according to the Dscore values, whereas NP1, NP5,
and NP6 appear to be diﬃcult sites and NP3 is not druggable.
In this case, NP3 may be used to design dual ligands with high
aﬃnity using the proximal ATP and/or adjacent pockets used
by type IIA and type IIB inhibitors.
■ CONCLUSIONS
The present work describes an analysis of the ﬂexibility of the
p38α MAP kinase as deduced from the results of a 6 μs
accelerated MD calculation. PCA was used to analyze protein
dynamics, and cluster analysis was used to select a set of a few
conﬁgurations representing the ensemble. PCA suggests that
the major components of the movement of the p38α protein
are related to relative movements of the C-terminal and N-
terminal domains. While the ﬁrst coordinate corresponds to the
bending motion of the two domains, the second involves a
rocking motion. Thus, both components describe the opening
and closing movements of the interlobular space that are
related to the activation-inactivation of protein kinases.
Projection of the structures sampled along the MD trajectory
onto the two ﬁrst principal components provides the free
energy surface that exhibits two minima. From the analysis of
the R-Spine motif, it can be concluded that the lowest energy
minimum (minimum 1) is represented by an inactive
conformation type IV, while the minimum 2 is represented
by a type III inactive conformation.
The representative structures from the cluster analysis were
screened for hot spots using FTMap. The procedure permitted
the identiﬁcation of diverse allosteric sites in p38α already
described in the literature including the DFG pocket, the lipid
binding pocket, the DEF site, the docking groove, the CD and
ED sites, and the backside site as well as the A-loop regulatory
site recently reported. In addition, ten novel prospective sites
were identiﬁed on the surface of the p38α protein (listed from
NP1 to NP10), in most of the cases involving protein structural
elements that control kinase activation including the activation
loop, the catalytic loop, the αC helix, the L16 loop, and the
glycine-rich loop.
One of the novel sites identiﬁed (NP3) appears due to the
adoption by the protein of the inactive αC-out conformation,
which allows access to an allosteric site used by a type III
inhibitor that binds to CDK2, that is adjacent to other allosteric
pockets used by type IIB and type III kinase inhibitors.
Inhibitors of the EGFR and B-Raf kinases, lapatinib and
vemurafenib, and inhibitor of MEK1 and MEK2, trametinib,
bind to these allosteric pockets and are currently approved by
the FDA for the treatment of advanced breast cancer and
melanoma. The present study suggests that this could be a
good strategy for the inhibition of p38α, or even other proteins
of the family of MAPKs, where type I inhibitors could be
derived into the NP3 pocket. Another interesting ﬁnding is the
identiﬁcation of the prospective site (NP5), located in a self-
inhibited conformation of p38α, in which the activation loop is
folded toward the ATP site, which is similar to that present in a
group of deposited JNK3 crystal structures in the PDB (PDB
ID: 4H36, 4H39, and 4H3B). The stabilization of this self-
Table 1. Druggability Assessment for Each of the Binding
Sites Identiﬁed in p38α in the Present Worka
aList of the SiteScore and Dscore values computed with SiteMap. The
gray color indicates site with SiteScore > 0.80, whereas green
corresponds to values of Dscore > 0.98; blue corresponds to the
interval 0.98−0.83.
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inhibited conformation by binding of a ligand at the NP5 site
could also be exploited as a therapeutic strategy.
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